TY - JOUR
T1 - Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping
AU - Beadling, Carol
AU - Neff, Tanaya L.
AU - Heinrich, Michael C.
AU - Rhodes, Katherine
AU - Thornton, Michael
AU - Leamon, John
AU - Andersen, Mark
AU - Corless, Christopher L.
N1 - Funding Information:
Supported in part by a merit review grant from the Department of Veterans Affairs (M.C.H.) and by funds from the GIST Cancer Research Fund (M.C.H., C.L.C.) and the Life Raft Group (M.C.H.).
Funding Information:
Disclosures: M.C.H. receives research funding from Novartis, Ariad, Imclone , and AROG, is a consultant for Novartis, Pfizer, and MolecularMD, and holds equity interest in MolecularMD. K.R., M.T., J.L., and M.A. are employees of Ion Torrent by Life Technologies, which manufactures some of the assay platforms examined herein. C.L.C. receives research funding from Novartis and consulting fees from Novartis, Pfizer, and MolecularMD, and is on the speakers bureau of Ion Torrent by Life Technologies and Pfizer.
PY - 2013/3
Y1 - 2013/3
N2 - There is growing demand for routine identification of actionable mutations in clinical cancer specimens. Genotyping platforms must provide rapid turnaround times and work effectively with limited amounts of formalin-fixed, paraffin-embedded (FFPE) tissue specimens that often yield poor quality DNA. We describe semiconductor-based sequencing of DNA from FFPE specimens using a single-tube, multiplexed panel of 190 amplicons targeting 46 cancer genes. With just 10 ng of input DNA, average read depths of 2000× can be obtained in 48 hours, with >95% of the reads on target. A validation set of 45 FFPE tumor specimens containing 53 point mutations previously identified with a mass spectrometry-based genotyping platform, along with 19 indels ranging from 4 to 63 bp, was used to evaluate assay performance. With a mutant allele ratio cutoff of 8%, we were able to achieve 100% sensitivity (95% CI = 97.3% to 100.0%) and 95.1% specificity (95% CI = 91.8% to 98.0%) of point mutation detection. All indels were visible by manual inspection of aligned reads; 6/9 indels ≤12 bp long were detected by the variant caller software either exactly or as mismatched nucleotides within the indel region. The rapid turnaround time and low input DNA requirements make the multiplex PCR and semiconductor-based sequencing approach a viable option for mutation detection in a clinical laboratory.
AB - There is growing demand for routine identification of actionable mutations in clinical cancer specimens. Genotyping platforms must provide rapid turnaround times and work effectively with limited amounts of formalin-fixed, paraffin-embedded (FFPE) tissue specimens that often yield poor quality DNA. We describe semiconductor-based sequencing of DNA from FFPE specimens using a single-tube, multiplexed panel of 190 amplicons targeting 46 cancer genes. With just 10 ng of input DNA, average read depths of 2000× can be obtained in 48 hours, with >95% of the reads on target. A validation set of 45 FFPE tumor specimens containing 53 point mutations previously identified with a mass spectrometry-based genotyping platform, along with 19 indels ranging from 4 to 63 bp, was used to evaluate assay performance. With a mutant allele ratio cutoff of 8%, we were able to achieve 100% sensitivity (95% CI = 97.3% to 100.0%) and 95.1% specificity (95% CI = 91.8% to 98.0%) of point mutation detection. All indels were visible by manual inspection of aligned reads; 6/9 indels ≤12 bp long were detected by the variant caller software either exactly or as mismatched nucleotides within the indel region. The rapid turnaround time and low input DNA requirements make the multiplex PCR and semiconductor-based sequencing approach a viable option for mutation detection in a clinical laboratory.
UR - http://www.scopus.com/inward/record.url?scp=84874533657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874533657&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2012.09.003
DO - 10.1016/j.jmoldx.2012.09.003
M3 - Article
C2 - 23274167
AN - SCOPUS:84874533657
SN - 1525-1578
VL - 15
SP - 171
EP - 176
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
IS - 2
ER -